Monotherapy should not be used as viral cross-resistance may develop if used alone or added as a sole agent to a failing regimen.
Liver function monitoring recommended for all patients.
Not recommended in patients with moderate to severe hepatic impairment.
Late-onset neurotoxicity may occur months to years after beginning therapy, especially in patients with CYP2B6 genetic polymorphisms associated with increased efavirenz levels; discontinuation may be warranted.
Immediate medical evaluation recommended for serious psychiatric symptoms.
Negative pregnancy test warranted prior to therapy initiation.